These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37496600)

  • 1. Carbapenem-Resistant
    Giannella M; Verardi S; Karas A; Abdel Hadi H; Dupont H; Soriano A; Santerre Henriksen A; Cooper A; Falcone M;
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad329. PubMed ID: 37496600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
    Falcone M; Tiseo G; Leonildi A; Della Sala L; Vecchione A; Barnini S; Farcomeni A; Menichetti F
    Antimicrob Agents Chemother; 2022 May; 66(5):e0214221. PubMed ID: 35311522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol treatment for carbapenem-resistant
    Pascale R; Pasquini Z; Bartoletti M; Caiazzo L; Fornaro G; Bussini L; Volpato F; Marchionni E; Rinaldi M; Trapani F; Temperoni C; Gaibani P; Ambretti S; Barchiesi F; Viale P; Giannella M
    JAC Antimicrob Resist; 2021 Dec; 3(4):dlab174. PubMed ID: 34806011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant
    Mazzitelli M; Gregori D; Sasset L; Trevenzoli M; Scaglione V; Lo Menzo S; Marinello S; Mengato D; Venturini F; Tiberio I; Navalesi P; Cattelan A
    Microorganisms; 2023 Apr; 11(4):. PubMed ID: 37110408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol Versus Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream Infections: A Retrospective, Propensity-Score Adjusted, Monocentric Cohort Study.
    Bavaro DF; Papagni R; Belati A; Diella L; De Luca A; Brindicci G; De Gennaro N; Di Gennaro F; Romanelli F; Stolfa S; Ronga L; Mosca A; Pomarico F; Dell'Aera M; Stufano M; Dalfino L; Grasso S; Saracino A
    Infect Dis Ther; 2023 Aug; 12(8):2147-2163. PubMed ID: 37653122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant
    Campogiani L; Crea AMA; Minardi ML; Ansaldo L; Coppola L; Compagno M; Vitale P; Spalliera I; Malagnino V; Teti E; D'agostini C; Pennacchiotti C; Abate DN; Celeste MG; Andreoni M; Iannetta M; Sarmati L
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad627. PubMed ID: 38156051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19.
    Russo A; Bruni A; Gullì S; Borrazzo C; Quirino A; Lionello R; Serapide F; Garofalo E; Serraino R; Romeo F; Marascio N; Matera G; Longhini F; Trecarichi EM; Torti C
    Int J Antimicrob Agents; 2023 Jul; 62(1):106825. PubMed ID: 37088438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol-containing regimens for the treatment of carbapenem-resistant
    Rando E; Cutuli SL; Sangiorgi F; Tanzarella ES; Giovannenze F; De Angelis G; Murri R; Antonelli M; Fantoni M; De Pascale G
    JAC Antimicrob Resist; 2023 Aug; 5(4):dlad085. PubMed ID: 37484029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant
    Dalfino L; Stufano M; Bavaro DF; Diella L; Belati A; Stolfa S; Romanelli F; Ronga L; Di Mussi R; Murgolo F; Loconsole D; Chironna M; Mosca A; Montagna MT; Saracino A; Grasso S
    Antibiotics (Basel); 2023 Jun; 12(6):. PubMed ID: 37370367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
    Corcione S; De Benedetto I; Pinna SM; Vita D; Lupia T; Montrucchio G; Brazzi L; De Rosa FG
    J Infect Public Health; 2022 Sep; 15(9):975-979. PubMed ID: 35961239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections.
    Gavaghan V; Miller JL; Dela-Pena J
    Infection; 2023 Apr; 51(2):475-482. PubMed ID: 36201152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol.
    Gatti M; Bartoletti M; Cojutti PG; Gaibani P; Conti M; Giannella M; Viale P; Pea F
    J Glob Antimicrob Resist; 2021 Dec; 27():294-298. PubMed ID: 34710630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF).
    Gatti M; Rinaldi M; Tonetti T; Gaibani P; Siniscalchi A; Viale P; Pea F
    Int J Antimicrob Agents; 2023 Aug; 62(2):106852. PubMed ID: 37192727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
    Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empiric treatment of patients with sepsis and septic shock and place in therapy of cefiderocol: a systematic review and expert opinion statement.
    Cortegiani A; Ingoglia G; Ippolito M; Girardis M; Falcone M; Pea F; Pugliese F; Stefani S; Viale P; Giarratano A
    J Anesth Analg Crit Care; 2022 Jul; 2(1):34. PubMed ID: 37386663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of cefiderocol for resistant Gram-negative infections: a real-life, single-centre experience.
    Karruli A; Massa A; Andini R; Marrazzo T; Ruocco G; Zampino R; Durante-Mangoni E
    Int J Antimicrob Agents; 2023 Feb; 61(2):106723. PubMed ID: 36642233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.